<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116618</url>
  </required_header>
  <id_info>
    <org_study_id>20-1193.cc</org_study_id>
    <nct_id>NCT05116618</nct_id>
  </id_info>
  <brief_title>Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged</brief_title>
  <official_title>Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inivata</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the detection rate of driver oncogenes and resistance mechanisms in&#xD;
      cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS)&#xD;
      progression) and concordance with plasma/tissue&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the detection rate of driver oncogenes and resistance mechanisms in&#xD;
      cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS)&#xD;
      progression) and concordance with plasma/tissue&#xD;
&#xD;
        -  For each individual patient with CNS progression (with or without eCNS progression),&#xD;
           compare the molecular status (primary oncogene detection and any mechanisms of&#xD;
           identifiable resistance including EGFR-, ALK- and ROS1-mutations, ALK-amplification and&#xD;
           bypass-tracks activating mutations) of CSF, plasma and CNS tissue (if data from&#xD;
           pathology report is available)&#xD;
&#xD;
        -  Molecular status will also be compared with previously obtained and stored plasma/tissue&#xD;
           prior to the initiation of current next-generation tyrosine-kinase inhibitor (TKI)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the detection rate of driver oncogenes and resistance mechanisms in cerebrospinal fluid (CSF) for patients with CNS progression (with or without extra-CNS (eCNS) progression) and concordance with plasma/tissue</measure>
    <time_frame>3 years</time_frame>
    <description>For each individual patient with CNS progression (with or without eCNS progression), compare the molecular status (primary oncogene detection and any mechanisms of identifiable resistance including EGFR-, ALK- and ROS1-mutations, ALK-amplification and bypass-tracks activating mutations) of CSF, plasma and CNS tissue (if data from pathology report is available)&#xD;
Molecular status will also be compared with previously obtained and stored plasma/tissue prior to the initiation of current next-generation tyrosine-kinase inhibitor (TKI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare and contrast mechanisms of resistance in CNS progression versus eCNS progression</measure>
    <time_frame>3 years</time_frame>
    <description>For patients with both CNS and eCNS progression, compare distribution of resistance mechanisms between CSF, plasma, CNS tissue (if data from pathology report is available) and tissue from site of eCNS progression (if data from pathology report is available)&#xD;
Compare distribution of resistance mechanisms in CSF for all patients with CNS progression (with or without eCNS progression) to historical data of distribution of resistance mechanisms to next-generation TKI from ctDNA/tumor tissue samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the clinical outcomes of subsequent lines of therapy base on CNS data from this study</measure>
    <time_frame>3 years</time_frame>
    <description>PFS and ORR in CNS</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine the clinical outcomes of subsequent lines of therapy base on eCNS data from this study</measure>
    <time_frame>3 years</time_frame>
    <description>PFS and ORR in eCNS</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine the safety of CSF sampling for detection of resistance mechanisms in the context of CNS progression</measure>
    <time_frame>3 years</time_frame>
    <description>AEs associated with procedure</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>10 evaluable enrollments to Cohort 1 with EGFR-mutant NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>10 evaluable enrollments to Cohort 2 with ALK-rearranged NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>10 evaluable enrollments to Cohort 3 with ROS1-rearranged NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>InVisionFirst-Lung ctDNA assay</intervention_name>
    <description>An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage IV EGFR, ALK, or ROS1-mutant NSCLC who had CNS progression after at&#xD;
        least 6 months of stable CNS disease on a relevant TKI are screened. Patients must meet all&#xD;
        Inclusion/Exclusion Criteria to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision to sign and date the consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and be available for the&#xD;
             duration of the study.&#xD;
&#xD;
          3. Be aged 18 or older.&#xD;
&#xD;
          4. Pathologically confirmed NSCLC with EGFR-mutation, or ALK- or ROS1-rearrangement and&#xD;
             currently on an EGFR, or ALK or ROS1 tyrosine-kinase inhibitor (TKI) as applicable&#xD;
&#xD;
          5. Stage IV NSCLC disease according to AJCC 8th edition&#xD;
&#xD;
          6. Known CNS metastasis prior to current line of therapy with CR/PR/SD for at least 6&#xD;
             months (not purely attributable to prior local therapy such as radiation) on current&#xD;
             EGFR, or ALK or ROS1 TKI, confirmed by at least one of the following modalities:&#xD;
&#xD;
               -  CT/MRI for brain metastases&#xD;
&#xD;
               -  characteristic signs and/or symptoms indicating progression,&#xD;
&#xD;
               -  cytology,&#xD;
&#xD;
               -  imaging findings for leptomeningeal disease&#xD;
&#xD;
          7. Confirmed current CNS progression, with or without eCNS progression, on the same TKI&#xD;
             based on at least one of the following modalities:&#xD;
&#xD;
               -  CT/MRI for brain metastases&#xD;
&#xD;
               -  characteristic signs and/or symptoms indicating progression,&#xD;
&#xD;
               -  cytology,&#xD;
&#xD;
               -  imaging findings for leptomeningeal disease&#xD;
&#xD;
          8. Prior CNS radiation therapy is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has contraindications to receive a lumbar puncture which may include, but are not&#xD;
             limited to the following, at the discretion of the patient's oncologist or physician&#xD;
             performing the LP:&#xD;
&#xD;
               -  Clinical and/or radiographic evidence of mass effect of raised intracranial&#xD;
                  pressure (ICP) with risk for cerebral herniation&#xD;
&#xD;
               -  Thrombocytopenia (defined as platelet count ≤ 50 or per local guidelines) or&#xD;
                  other bleeding diathesis&#xD;
&#xD;
               -  Currently on antiplatelet or anticoagulant therapy at time of consent, for which&#xD;
                  the thrombosis risk of holding for LP is deemed unacceptable&#xD;
&#xD;
               -  Suspected spinal epidural abscess&#xD;
&#xD;
               -  Any other condition determined by the clinician to be a contraindication&#xD;
&#xD;
          2. History of a second primary malignancy (including a second primary lung cancer) with&#xD;
             the exceptions for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥5&#xD;
                  years, and of low potential risk for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          3. Women who are documented as pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Camidge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cole Sprague</last_name>
    <phone>17208488030</phone>
    <email>cole.sprague@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Berens</last_name>
    <email>emily.berens@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cole Sprague</last_name>
      <phone>720-848-8030</phone>
      <email>cole.sprague@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Berens</last_name>
      <email>emily.berens@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ross Camidge</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Bunn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Goldin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denise M Damek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Han-Voth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Ney</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Pacheco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tejas Patil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Tom Purcell</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Candice Rossi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Schenk</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun Cheong Tsui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCHealth Metro Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>720-848-0650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progression</keyword>
  <keyword>Central Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>whole study will be presented</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

